A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

News

News

All the latest news about the Access to Medicine Foundation, our research programmes and engagement activities. 

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

03 Dec 2021

Jane Masiga and Patrick Flochel bring breadth of experience as new Supervisory Board members

Jane Masiga and Patrick Flochel have joined the Supervisory Board of the Access to Medicine Foundation, in two significant appointments that will help...

18 Nov 2021

Signs of progress by pharma against superbugs, yet little movement to address access

Pharma companies press on in fight against superbugs despite COVID-19 pandemic, finds the 2021 Antimicrobial Resistance Benchmark. But action to impro...

02 Nov 2021

What are pharma companies doing to slow the superbugs? New report out soon.

Superbugs threaten to cause the next pandemic. On Thursday 18 November, the Access to Medicine Foundation will publish the 2021 Antimicrobial Res...

22 Sep 2021

New Index methodology: capacity to track progress prioritised for 2022

The Methodology Report for the next Access to Medicine Index is now online. It sets out the metrics the Access to Medicine Foundation will use in 2022...

13 Jul 2021

7 lessons from COVID-19 for pharma companies

There is a long way to go to curb the COVID-19 pandemic. To speed the end of the pandemic, and support a recovery that leaves no-one behind, the Acces...

22 Jun 2021

Foundation names Expert Review Committee for 2022 Access to Medicine Index

The Access to Medicine Foundation is pleased to announce the members of the Expert Review Committee for the next Access to Medicine Index, including f...

16 Jun 2021

Global oxygen suppliers commit to closing oxygen gaps in low- and middle-income countries

Two of the world’s largest medical oxygen suppliers have agreed to work with the COVID-19 Oxygen Emergency Taskforce to increase access to medical oxy...

10 Jun 2021

Biotech’s antibiotic warriors need new reward system in superbug fight

Today, a new report by the Foundation examines how small drugmakers, which are pivotal in antibiotic development, are navigating the to...

25 Mar 2021

Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?

New analysis: Just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in paediatric treatment options.

22 Mar 2021

Foundation welcomes new tool to tackle AMR by enhancing stewardship and access plans

A working group of experts, led by Wellcome Trust, have developed the first ever comprehensive Stewardship and Access Plan (SAP) Development Guide. Pu...

23 Feb 2021

Investors issue urgent call for “fair and equitable” global response to COVID-19

Today, almost 150 institutional investors have issued a joint call for a fair and equitable global response to the pandemic, including through fully f...

26 Jan 2021

Now online: 2021 Access to Medicine Index

Pharma companies move to systematically make new medicines rapidly accessible to the poor. The 2021 Access to Medicine Index identifies eight pha...

24 Nov 2020

The materiality of superbugs: risks and opportunities for pharma investors from antimicrobial resistance

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimic...

23 Nov 2020

First investor partners named in joint initiative against 'super-sized' AMR threat

As World Antimicrobial Awareness Week begins, 12 global investors and financial institutions have announced they are joining the Investor Action on AM...

20 Nov 2020

Sharing surveillance data: the value of collaboration in curbing the next pandemic

Monitoring the spread of infectious diseases through surveillance programmes is fundamental to maintaining good public health and a key component of s...

20 Oct 2020

Bridging the gap in access to oxygen: Foundation coordinates on key actions for industry

Oxygen is critical in the treatment of pneumonia, which claims the lives of more than 672,000 children under 5 every year. Further, one in five COVID-...

Back to top |